Deferasirox: an orphan drug for chronic iron overload in non-transfusion dependent thalassemia syndromes

References

• Weatherall DJ, Clegg JB. The thalassaemia syndromes. 4th ed. Oxford: Blackwell Science; 2001.
   Google Scholar
• Harteveld CL, Higgs DR. Alpha-thalassaemia. Orphanet J Rare Dis. 2010;5:13.
   PubMed Web of Science ®Google Scholar
• Galanello R, Origa R. Beta-thalassemia. Orphanet J Rare Dis. 2010;5:11.
   PubMed Web of Science ®Google Scholar
• Weatherall DJ, Clegg JB. Inherited haemoglobin disorders: an increasing global health problem. Bull World Health Organ. 2001;79(8):704–712.
   PubMed Web of Science ®Google Scholar
• Taher AT, Radwan A, Viprakasit V. When to consider transfusion therapy for patients with non-transfusion-dependent thalassaemia. Vox Sang. 2015;108(1):1–10.
   PubMed Web of Science ®Google Scholar
• Taher A, Vichinsky E, Musallam K, et al. Iron overload and chelation therapy. In: Weatherall D, editor. Guidelines for the Management of Non Transfusion Dependent Thalassaemia (NTDT). Nicosia, Cyprus: Thalassaemia International Federation;2013.
   Google Scholar
• Weatherall DJ. The definition and epidemiology of non-transfusion-dependent thalassemia. Blood Rev. 2012;26(Suppl 1):S3–S6.
   PubMed Web of Science ®Google Scholar
• Musallam KM, Khoury B, Abi-Habib R, et al. Health-related quality of life in adults with transfusion-independent thalassaemia intermedia compared to regularly transfused thalassaemia major: new insights. Eur J Haematol. 2011;87(1):73–79.
   PubMed Web of Science ®Google Scholar
• Viprakasit V, Tyan P, Rodmai S, et al. Identification and key management of non-transfusion-dependent thalassaemia patients: not a rare but potentially under-recognised condition. Orphanet J Rare Dis. 2014;9:131.
   PubMed Web of Science ®Google Scholar
• Vichinsky E. Non-transfusion-dependent thalassemia and thalassemia intermedia: epidemiology, complications, and management. Curr Med Res Opin. 2016;32(1):191–204.
   PubMed Web of Science ®Google Scholar
• Fucharoen S, Ketvichit P, Pootrakul P, et al. Clinical manifestation of beta-thalassemia/hemoglobin E disease. J Pediatr Hematol Oncol. 2000;22(6):552–557.
   PubMed Web of Science ®Google Scholar
• Musallam KM, Taher AT, Rachmilewitz EA. beta-thalassemia intermedia: a clinical perspective. Cold Spring Harb Perspect Med. 2012;2(7):a013482.
   PubMed Web of Science ®Google Scholar
• Taher A, Isma’eel H, Cappellini MD. Thalassemia intermedia: revisited. Blood Cells Mol Dis. 2006;37(1):12–20.
   PubMed Web of Science ®Google Scholar
• Taher AT, Musallam KM, Karimi M, et al. Overview on practices in thalassemia intermedia management aiming for lowering complication rates across a region of endemicity: the OPTIMAL CARE study. Blood. 2010;115(10):1886–1892.
   PubMed Web of Science ®Google Scholar
• Taher AT, Musallam KM, Karimi M, et al. Splenectomy and thrombosis: the case of thalassemia intermedia. J Thromb Haemostasis: JTH. 2010;8(10):2152–2158.
   PubMed Web of Science ®Google Scholar
• Pippard MJ, Callender ST, Warner GT, et al. Iron absorption and loading in beta-thalassaemia intermedia. Lancet (London, England). 1979;2(8147):819–821.
   PubMed Web of Science ®Google Scholar
• Gardenghi S, Grady RW, Rivella S. Anemia, ineffective erythropoiesis, and hepcidin: interacting factors in abnormal iron metabolism leading to iron overload in beta-thalassemia. Hematol Oncol Clin North Am. 2010;24(6):1089–1107.
   PubMed Web of Science ®Google Scholar
• Tanno T, Miller JL. Iron loading and overloading due to ineffective erythropoiesis. Adv Hematol. 2010;2010:358283.
   PubMedGoogle Scholar
• Tanno T, Bhanu NV, Oneal PA, et al. High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin. Nat Med. 2007;13(9):1096–1101.
   PubMed Web of Science ®Google Scholar
• Tanno T, Porayette P, Sripichai O, et al. Identification of TWSG1 as a second novel erythroid regulator of hepcidin expression in murine and human cells. Blood. 2009;114(1):181–186.
   PubMed Web of Science ®Google Scholar
• Origa R, Galanello R, Ganz T, et al. Liver iron concentrations and urinary hepcidin in beta-thalassemia. Haematologica. 2007;92(5):583–588.
   PubMed Web of Science ®Google Scholar
• Taher A, Musallam KM, El Rassi F, et al. Levels of non-transferrin-bound iron as an index of iron overload in patients with thalassaemia intermedia. Br J Haematol. 2009;146(5):569–572.
   PubMed Web of Science ®Google Scholar
• Restivo Pantalone G, Renda D, Valenza F, et al. Hepatocellular carcinoma in patients with thalassaemia syndromes: clinical characteristics and outcome in a long term single centre experience. Br J Haematol. 2010;150(2):245–247.
   PubMed Web of Science ®Google Scholar
• Mancuso A. Hepatocellular carcinoma in thalassemia: A critical review. World J Hepatol. 2010;2(5):171–174.
   PubMedGoogle Scholar
• Musallam KM, Cappellini MD, Wood JC, et al. Elevated liver iron concentration is a marker of increased morbidity in patients with beta thalassemia intermedia. Haematologica. 2011;96(11):1605–1612.
   PubMed Web of Science ®Google Scholar
• Ziyadeh FN, Musallam KM, Mallat NS, et al. Glomerular hyperfiltration and proteinuria in transfusion-independent patients with beta-thalassemia intermedia. Nephron Clinical Practice. 2012;121(3–4):c136–c143.
   PubMed Web of Science ®Google Scholar
• Musallam KM, Nasreddine W, Beydoun A, et al. Brain positron emission tomography in splenectomized adults with beta-thalassemia intermedia: uncovering yet another covert abnormality. Ann Hematol. 2012;91(2):235–241.
   PubMed Web of Science ®Google Scholar
• Musallam KM, Beydoun A, Hourani R, et al. Brain magnetic resonance angiography in splenectomized adults with beta-thalassemia intermedia. Eur J Haematol. 2011;87(6):539–546.
   PubMed Web of Science ®Google Scholar
• Origa R, Barella S, Argiolas GM, et al. No evidence of cardiac iron in 20 never- or minimally-transfused patients with thalassemia intermedia. Haematologica. 2008;93(7):1095–1096.
   PubMed Web of Science ®Google Scholar
• Taher AT, Musallam KM, Wood JC, et al. Magnetic resonance evaluation of hepatic and myocardial iron deposition in transfusion-independent thalassemia intermedia compared to regularly transfused thalassemia major patients. Am J Hematol. 2010;85(4):288–290.
   PubMed Web of Science ®Google Scholar
• Roghi A, Cappellini MD, Wood JC, et al. Absence of cardiac siderosis despite hepatic iron overload in Italian patients with thalassemia intermedia: an MRI T2* study. Ann Hematol. 2010;89(6):585–589.
   PubMed Web of Science ®Google Scholar
• Mavrogeni S, Gotsis E, Ladis V, et al. Magnetic resonance evaluation of liver and myocardial iron deposition in thalassemia intermedia and b-thalassemia major. Int J Cardiovasc Imaging. 2008;24(8):849–854.
   PubMed Web of Science ®Google Scholar
• Musallam KM, Cappellini MD, Wood JC, et al. Iron overload in non-transfusion-dependent thalassemia: a clinical perspective. Blood Rev. 2012;26(Suppl 1):S16–S19.
   PubMed Web of Science ®Google Scholar
• Taher AT, Porter J, Viprakasit V, et al. Deferasirox reduces iron overload significantly in nontransfusion-dependent thalassemia: 1-year results from a prospective, randomized, double-blind, placebo-controlled study. Blood. 2012;120(5):970–977.
   PubMed Web of Science ®Google Scholar
• Taher AT, Musallam KM, El-Beshlawy A, et al. Age-related complications in treatment-naive patients with thalassaemia intermedia. Br J Haematol. 2010;150(4):486–489.
   PubMed Web of Science ®Google Scholar
• Musallam KM, Cappellini MD, Daar S, et al. Serum ferritin level and morbidity risk in transfusion-independent patients with beta-thalassemia intermedia: the ORIENT study. Haematologica. 2014;99(11):e218–e2121.
   PubMed Web of Science ®Google Scholar
• Lal A, Goldrich ML, Haines DA, et al. Heterogeneity of hemoglobin H disease in childhood. N Engl J Med. 2011;364(8):710–718.
   PubMed Web of Science ®Google Scholar
• Taher A, El Rassi F, Isma’eel H, et al. Correlation of liver iron concentration determined by R2 magnetic resonance imaging with serum ferritin in patients with thalassemia intermedia. Haematologica. 2008;93(10):1584–1586.
   PubMed Web of Science ®Google Scholar
• Pakbaz Z, Fischer R, Fung E, et al. Serum ferritin underestimates liver iron concentration in transfusion independent thalassemia patients as compared to regularly transfused thalassemia and sickle cell patients. Pediatr Blood Cancer. 2007;49(3):329–332.
   PubMed Web of Science ®Google Scholar
• Angelucci E, Brittenham GM, McLaren CE, et al. Hepatic iron concentration and total body iron stores in thalassemia major. N Engl J Med. 2000;343(5):327–331.
   PubMed Web of Science ®Google Scholar
• Wood JC. Impact of iron assessment by MRI. Hematol /the Educ Program Am Soc Hematol Am Soc Hematol Educ Program. 2011;2011:443–450.
   PubMed Web of Science ®Google Scholar
• Musallam KM, Cappellini MD, Taher AT. Evaluation of the 5mg/g liver iron concentration threshold and its association with morbidity in patients with beta-thalassemia intermedia. Blood Cells Mol Dis. 2013;51(1):35–38.
   PubMed Web of Science ®Google Scholar
• Taher AT, Porter JB, Viprakasit V, et al. Approaching low liver iron burden in chelated patients with non-transfusion-dependent thalassemia: the safety profile of deferasirox. Eur J Haematol. 2014;92(6):521–526.
   PubMed Web of Science ®Google Scholar
• Cheong JW, Kim HJ, Lee KH, et al. Deferasirox improves hematologic and hepatic function with effective reduction of serum ferritin and liver iron concentration in transfusional iron overload patients with myelodysplastic syndrome or aplastic anemia. Transfusion. 2014;54(6):1542–1551.
   PubMed Web of Science ®Google Scholar
• Olivieri NF, Brittenham GM, Matsui D, et al. Iron-chelation therapy with oral deferipronein patients with thalassemia major. N Engl J Med. 1995;332(14):918–922.
   PubMed Web of Science ®Google Scholar
• Brittenham GM, Cohen AR, McLaren CE, et al. Hepatic iron stores and plasma ferritin concentration in patients with sickle cell anemia and thalassemia major. Am J Hematol. 1993;42(1):81–85.
   PubMed Web of Science ®Google Scholar
• Eghbali A, Taherahmadi H, Shahbazi M, et al. Association between serum ferritin level, cardiac and hepatic T2-star MRI in patients with major beta-thalassemia. Iran J Pediatr Hem Oncol. 2014;4(1):17–21.
   PubMedGoogle Scholar
• Taher AT, Porter JB, Viprakasit V, et al. Defining serum ferritin thresholds to predict clinically relevant liver iron concentrations for guiding deferasirox therapy when MRI is unavailable in patients with non-transfusion-dependent thalassaemia. Br J Haematol. 2015;168(2):284–290.
   PubMed Web of Science ®Google Scholar
• Cossu P, Toccafondi C, Vardeu F, et al. Iron overload and desferrioxamine chelation therapy in beta-thalassemia intermedia. Eur J Pediatr. 1981;137(3):267–271.
   PubMed Web of Science ®Google Scholar
• Pippard MJ, Weatherall DJ. Iron balance and the management of iron overload in beta-thalassemia intermedia. Birth Defects Orig Artic Ser. 1988;23(5b):29–33.
   PubMedGoogle Scholar
• Olivieri NF, Koren G, Matsui D, et al. Reduction of tissue iron stores and normalization of serum ferritin during treatment with the oral iron chelator L1 in thalassemia intermedia. Blood. 1992;79(10):2741–2748.
   PubMed Web of Science ®Google Scholar
• Pootrakul P, Sirankapracha P, Sankote J, et al. Clinical trial of deferiprone iron chelation therapy in beta-thalassaemia/haemoglobin E patients in Thailand. Br J Haematol. 2003;122(2):305–310.
   PubMed Web of Science ®Google Scholar
• Rombos Y, Tzanetea R, Konstantopoulos K, et al. Chelation therapy in patients with thalassemia using the orally active iron chelator deferiprone (L1). Haematologica. 2000;85(2):115–117.
   PubMed Web of Science ®Google Scholar
• Akrawinthawong K, Chaowalit N, Chatuparisuth T, et al. Effectiveness of deferiprone in transfusion-independent beta-thalassemia/HbE patients. Hematology. 2011;16(2):113–122.
   PubMed Web of Science ®Google Scholar
• Chan JC, Chim CS, Ooi CG, et al. Use of the oral chelator deferiprone in the treatment of iron overload in patients with Hb H disease. Br J Haematol. 2006;133(2):198–205.
   PubMed Web of Science ®Google Scholar
• Novartis Pharmaceuticals Corporation. EXJADE®(deferasirox) tablets, for oral suspension. [updated 2015 Jul; cited 2016 Feb 16]. Available from: https://www.pharma.us.novartis.com/product/pi/pdf/exjade.pdf
   Google Scholar
• Committee for Medicinal Products for Human Use. Exjade. [updated 2013 May 25; cited 2016 Feb 16]; Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/000670/WC500146154.pdf
   Google Scholar
• Novartis Pharmaceuticals Corporation. JADENU TM (deferasirox) tablets, for oral use. [updated 2015 Mar; cited 2016 Feb 16]; Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206910s000lbl.pdf
   Google Scholar
• Keshtkaran A, Javanbakht M, Salavati S, et al. Cost-utility analysis of oral deferasirox versus infusional deferoxamine in transfusion-dependent beta-thalassemia patients. Transfusion. 2013;53(8):1722–1729.
   PubMed Web of Science ®Google Scholar
• Karnon J, Tolley K, Vieira J, et al. Lifetime cost-utility analyses of deferasirox in beta-thalassaemia patients with chronic iron overload: a UK perspective. Clin Drug Investig. 2012;32(12):805–815.
   PubMed Web of Science ®Google Scholar
• Cappellini MD, Bejaoui M, Agaoglu L, et al. Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta-thalassemia. Clin Ther. 2007;29(5):909–917.
   PubMed Web of Science ®Google Scholar
• Taher AT, Viprakasit V, Musallam KM, et al. Treating iron overload in patients with non-transfusion-dependent thalassemia. Am J Hematol. 2013;88(5):409–415.
   PubMed Web of Science ®Google Scholar
• Taher AT, Cappellini MD, Aydinok Y, et al. Optimising iron chelation therapy with deferasirox for non-transfusion-dependent thalassaemia patients: 1-year results from the THETIS study. Blood Cells Mol Dis. 2016;57:23–29.
   PubMed Web of Science ®Google Scholar
• Steinhauser S, Heinz U, Bartholomä M, et al. Complex Formation of ICL670 and Related Ligands with FeIII and FeII. Eur J Inorg Chem. 2004;2004(21):4177–4192.
   Web of Science ®Google Scholar
• Waldmeier F, Bruin GJ, Glaenzel U, et al. Pharmacokinetics, metabolism, and disposition of deferasirox in beta-thalassemic patients with transfusion-dependent iron overload who are at pharmacokinetic steady state. Drug Metab Dispos. 2010;38(5):808–816.
   PubMed Web of Science ®Google Scholar
• Voskaridou E, Plata E, Douskou M, et al. Treatment with deferasirox (Exjade) effectively decreases iron burden in patients with thalassaemia intermedia: results of a pilot study. Br J Haematol. 2010;148(2):332–334.
   PubMed Web of Science ®Google Scholar
• Ladis V, Berdousi H, Gotsis E, et al. Deferasirox administration for the treatment of non-transfusional iron overload in patients with thalassaemia intermedia. Br J Haematol. 2010;151(5):504–508.
   PubMed Web of Science ®Google Scholar
• Taher AT, Porter JB, Viprakasit V, et al. Deferasirox effectively reduces iron overload in non-transfusion-dependent thalassemia (NTDT) patients: 1-year extension results from the THALASSA study. Ann Hematol. 2013;92(11):1485–1493.
   PubMed Web of Science ®Google Scholar
• Karimi M, Arandi N, Haghpanah S, et al. Efficacy of Deferasirox (Exjade(R)) in modulation of iron overload in patients with beta-thalassemia intermedia. Hemoglobin. 2015;39(5):327–329.
   PubMed Web of Science ®Google Scholar
• Taher AT, Porter JB, Viprakasit V, et al. Deferasirox demonstrates a dose-dependent reduction in liver iron concentration and consistent efficacy across subgroups of non-transfusion-dependent thalassemia patients. Am J Hematol. 2013;88(6):503–506.
   PubMed Web of Science ®Google Scholar
• Cappellini MD, Taher A. Long-term experience with deferasirox (ICL670), a once-daily oral iron chelator, in the treatment of transfusional iron overload. Expert Opin Pharmacother. 2008;9(13):2391–2402.
   PubMed Web of Science ®Google Scholar
• Cappellini MD, Cohen A, Piga A, et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood. 2006;107(9):3455–3462.
   PubMed Web of Science ®Google Scholar
• Lee JW, Yoon SS, Shen ZX, et al. Iron chelation therapy with deferasirox in patients with aplastic anemia: a subgroup analysis of 116 patients from the EPIC trial. Blood. 2010;116(14):2448–2454.
   PubMed Web of Science ®Google Scholar
• Hoffbrand AV, Taher A, Cappellini MD. How I treat transfusional iron overload. Blood. 2012;120(18):3657–3669.
   PubMed Web of Science ®Google Scholar
• Gardenghi S, Ramos P, Marongiu MF, et al. Hepcidin as a therapeutic tool to limit iron overload and improve anemia in beta-thalassemic mice. J Clin Invest. 2010;120(12):4466–4477.
   PubMed Web of Science ®Google Scholar
• Li H, Rybicki AC, Suzuka SM, et al. Transferrin therapy ameliorates disease in beta-thalassemic mice. Nat Med. 2010;16(2):177–182.
   PubMed Web of Science ®Google Scholar
• Rivella S. The role of ineffective erythropoiesis in non-transfusion-dependent thalassemia. Blood Rev. 2012;26(Suppl 1):S12–S15.
   PubMed Web of Science ®Google Scholar